Your access to the Tirzepatida in the unified health system-SUS it became a topic increasingly discussed in Brazil, the extent to which drugs like Mounjaro gained ground in the treatment of type 2 diabetes, and obesity.
The drug has already indications that are approved by the Fda and is commercially available in the country, but the cost is still a barrier for many people.
In 2026, the discussion has come to the Congress.
Bill no. 590/2026 proposes to include Mounjaro and Zepbound, drugs, based on the tirzepatida, in addition to other agonists of the GLP-1), on the Program, the Pharmacy, people in Brazil.
But it does mean that the Tirzepatida in the unified health system-SUS it will be distributed free of charge?
No.
There is a big difference between a bill has been introduced, and a drug actually going to be available for the public.
As of August of 2026, the project was still in the process of approval in the house of Representatives and the tirzepatida had not yet been built domestically in the unified health system-SUS) for these indications.
In this article, you are going to understand what's going on, that it is the project, how it works, the incorporation of the drug in the system, and what steps still need to take place.
- Important: this article contains for informational purposes only. The existence of the draft laws and discussions about the merger does not mean that the drug is already available, free of charge. All the information reflects the situation as seen in the August of 2026.
Tirzepatida in the unified health system-SUS: what is the situation now?
To the maintenance section of this article, the Tirzepatida in the unified health system-SUS yet it is not part of the bid to the national mainstream Health System for the treatment of obesity or type 2 diabetes.
The very Fda explained that a regulatory approval of a drug does not automatically mean that it will be provided by the unified health system-SUS.
For that to happen on a national level, it is usually necessary for an evaluation of the The National committee for the Incorporation of Technologies into the unified Health System (sus, in the Conitecand then the decision of the Ministry of Health.
The Fda makes it clear on their page on the re-appointment of the Mounjaro for the control of chronic, of the weight of the availability of the SUS is subject to the evaluation and recommendation of the Conitec, and the approval of the Ministry of Health.
So, we have two different issues:
Fda: evaluate if the product has a quality, safe, and effective for a particular indication.
SYSTEM/Conitec: it evaluates whether it should be built into the system, taking into account the clinical evidence, cost-effectiveness, and impact on the budget, and other factors.
There is a project to make the Mounjaro by the people's Pharmacy
Yes.
In February, 2026, was introduced in the house of Representatives of the Bill no. 590/2026.
The proposal to include in the Program to people's Pharmacy:
- Mounjaro;
- Zepbound;
- other drugs acting on the receptor, GLP-1 is proven to be effective.
The project speaks of the use of these medications for conditions such as:
- obesity.
- a chronic disease is based on the fatness;
- being overweight is a risk age;
- type 2 diabetes mellitus.
The proposal was introduced by congressman Pompeo de Mattos, and should be submitted to the Committees on Health, Finance, and Taxation and the Constitution, Justice and Citizenship.
In August of 2026, the situation, an official of the Chamber was composed, such as:
“Waiting for the Designation of the Rapporteur in the Committee on Health.”
That is, the project is still in phase with the initial procedure.
People's pharmacy-and the SUS are they the same thing?
Not really.
It is important to understand the discussion Tirzepatida in the unified health system-SUS.
The Program for the Pharmacy people, Brazil is the policy of the department of Health care that provides drugs and raw materials, by means of the the pharmacies in a private and accredited.
Currently, the program offers a drug-free for a number of conditions, such as:
- - hypertension;
- diabetes;
- - asthma;
- osteoporosis;
- dyslipidemia;
- allergic rhinitis;
- glaucoma;
- Parkinson's disease;
- contraception.
This means that, in the case of a medicinal product to be included in people's Pharmacy, your withdrawal may occur in the private establishments participating in the program, following the rules laid down by the Ministry of Health.
However, other medicines that system can be dispensed directly into the:
- The base units of the organization.
- pharmacy councils;
- specialized units;
- components of pharmaceutical care.
Therefore, the PL 590/2026 it does not represent exactly the use of a conventional Tirzepatida in the unified health system-SUS by the middle of the Conitec.
It also provides specifically for inclusion in the The Program People's Pharmacy.
What is the people's Pharmacy?
The people's Pharmacy, was established to expand the population's access to medicines is mainly used in Primary Health care.
The program functions by means of the pharmacies and drug stores, private settlement.
In 2026, the medicines and supplies that belong to a group of the programme are provided free of charge to patients who meet the rules of the retreat.
To get a drug on the program, it is usually necessary to present the required documents, such as income and valid identification from the individual patient.
But Mounjaro and tirzepatida are not currently part of the cast, an official from the people's Pharmacy.
For this reason, it is not possible to come in today for a pharmacy accredited by and ask for Mounjaro, free of charge, only for her to participate in the program.
The project has already been approved?
No.
This is probably the point, what more do you need to be highlighted.
The bill 590/2026 it is not an act in force.
As of August of 2026, he looked forward to the rapporteur in the Committee on Health of the house of Representatives.
The order's current provides an analysis of the following committees:
- The committee of the organization.
- Committee on Finance and Tax;
- Committee on Constitution, Justice and Citizenship.
The project is being tried under the ordinary regime.
Thus, although there are many different steps until it is a possible inclusion to become a reality.
It is for this reason that today's headlines:
“Mounjaro will be free of charge for the unified health system-SUS”
it would, in time, to be incorrect.
The most appropriate is to say:
there is currently a bill proposing to increase the access to the tirzepatida by the people's Pharmacy.
The project can be rejected?
Yes.
The bills are:
- to receive a favourable opinion;
- get opinion to the contrary.
- to be modified.
- to receive replacement;
- stay still during the procedure;
- to be filed;
- to be approved for.
There is no guarantee that the text that appears in the February 2026, which shall be approved in exactly the same way as has been proposed.
They can also arise from discussions about:
- the cost to the government.
- the criteria for nomination;
- the public would have access to them.
- the impact on the budget;
- the need for a prescription;
- use for obesity.
- use for diabetes
- professional follow-up.
For this reason, the discussion on the Tirzepatida in the unified health system-SUS it is still far from being considered as terminated.
Why we provide Tirzepatida by the public, it is a discussion of the complex?
One of the biggest challenges is the price.
Modern day medicines that are used in the treatment of chronic obesity may pose an impact on the budget too high to be considered to a large population.
Don't you just see how much does it cost to treat a single person.
To public policy, it is important to consider the potentially:
- in the hundreds of thousands,
- or, if not millions, of patients eligible for;
- the duration of the treatment;and
- the need for follow-up;
- possible dose adjustments;
- adverse effect;
- the benefits achieved.
- the economy is generated by the prevention of complications.
In this review, is one of the functions of the Conitec.
The Conitec does it do that?
The Conitec is responsible for assisting the Ministry of Health technology assessment, which can then be incorporated into the unified health system-SUS.
Among the factors evaluated are the following:
- effectively.
- it safe;
- benefits of clinical trials;
- compared to the treatments already available.
- cost-effectiveness;
- the impact on the budget.
Not enough medicine to work.
The commission needs to examine whether adoption is possible within a system that caters for more than 200 million brazilians and has limited resources.
Because of this, the drugs are approved by the Fda may not be available to you automatically by the public.
The other drugs for obesity, have been evaluated
Discussion Tirzepatida in the unified health system-SUS place in a larger context.
By 2025, for example, the Conitec rated semaglutida to a specific group: people with obesity grades II and III) and without diabetes, from a 45-year-old with heart disease is established.
The final recommendation was to are not included in the unified health system-SUS for such a statement.
Among other things, considered to be included:
- the high impact of the budget;
- uncertainty over the timing of the processing;
- the need to integrate the medication with other strategies for the elderly.
The estimates presented during the trial it came on the values of a billion dollars in five years, depending on the scenario considered.
Experience has shown that a possible merger of the tirzepatida it could also involve an economic analysis and very detailed.
And liraglutida?
The liraglutida have also passed the evaluation of Conitec by the year 2025, for the treatment of patients with obesity and type 2 diabetes mellitus.
The decision has also been the are not included in the unified health system-SUS that specific statement.
These precedents, it does not mean that the Tirzepatida in the unified health system-SUS not necessarily have the same results in the future.
For each technology and each nomination is evaluated individually.
But it shows that the cost and the impact on the budget have a significant role in decision-making.
Obesity is treated by the public at this time?
Yes.
Do not take medicines such as Mounjaro are available nationally, it does not mean that the SUS is not a case of obesity.
The system provides you with different strategies, which may include the following:
- medical follow-up;
- nutritional counseling;
- the promotion of physical activity;
- psychological care;
- care, multi-professional;
- the treatment of the diseases that are associated with;
- bariatric surgery in patients who meet the criteria.
The approach will depend on the situation of the patient and of the services available on the site.
The current debate is about how to add new options to the drug at this set of tools.
For the Tirzepatida draws so much attention.
To Tirzepatida in the unified health system-SUS it came to be discussed, especially after all of the results obtained in clinical trials, diabetes, and weight control.
A molecule which acts simultaneously on the recipients:
- GIP;
- LPG (liquefied petroleum gas-1.
In this study SURMOUNT-1, and a certain dose of tirzepatida produced reductions in the average weight of around 15% to 21%, after 72 weeks) in adults with obesity or overweight and without diabetes.
These results meant that the drugs in this class receive wide attention in the medical and popular.
However, the clinical outcomes of the significant do not address themselves to the question of access by the public.
Mounjaro is already approved for obesity in the united states?
Yes.
In June, in the year 2025, the Fda has approved a new indication for the Mounjaro.
The drug is now indicated for the control of chronic weight, including the loss and maintenance, in conjunction with a low-calorie diet and increased physical activity in adults:
- with a BMI equal to or greater than 30 kg/m2; or
- with a BMI equal to or greater than 27 kg/m2) and at least one condition related to your weight.
These include high blood pressure, dyslipidemia, obstructive sleep apnea, cardiovascular disease, pre-diabetes, and type 2 diabetes.
But then again:
approval by the Fda does not constitute the provision of Tirzepatida in the unified health system-SUS.
They are different processes.
Mounjaro and Zepbound have Tirzepatida
The bill 590/2026 quotes for both Mounjaro the Zepbound.
The two brands are related to the molecule's tirzepatida.
In Brazil, the most well-known is the Mounjaro.
In the United States, Zepbound is a trademark of the tirzepatida that is used for some of the information related to the control of body weight.
For this reason, the project makes use of brand names along with a reference to the substance.
From the point of view of public policy, however, on the way to the end-of-purchase and delivery will depend on the rules that were in place in case the proposal is to proceed.
Those who would have been entitled to if the project is approved or not?
This response is not yet defined in a practical way.
The project speaks of the drugs for obesity, a chronic disease that is based on the fat, being overweight is a risk, metabolic, and type 2 diabetes.
But it's possible the implementation of a policy, it may require the following criteria:
- diagnosis.
- IMC,
- the presence of co-morbid conditions;
- the history of the treatment;and
- the prescribing physician.
- regular follow-up.
It would be incorrect to say now, that anyone wanting to lose weight would be right.”
Even in private, Mounjaro have clinical signs specific to their sale to require a prescription.
The Tirzepatida would be for free?
If in the future the policy would require providing fully funded by the government, yes.
The people's Pharmacy is currently working with the medicines, and raw materials are free, and belonging to the squad in the official program.
But that would be contingent upon the approval and regulation of the proposal.
While this is not the case, there is no provision in the official withdrawal of the free Mounjaro at participating pharmacies.
Is there a date for the Tirzepatida to arrive at the unified health system-SUS?
No.
Currently, there is no official date for the release of the national Tirzepatida in the unified health system-SUS.
The bill 590/2026 is still in progress.
In addition to this, the possibility of incorporating in the conventional by the public will also depend on the process of valuation.
Therefore, in any of the sources, promising to:
“you will arrive at the unified health system-SUS, in just a month,”
without a formal decision should be viewed with caution.
Some cities are trying to address the topic
In addition to the federal project, in support of local initiatives have begun to appear.
In August of 2026, for example, at the city Hall in Mairinque, Sao Paulo, and has approved a request to provide information to the Ministry of Health regarding the availability of free pens for low-income individuals, with obesity and the diseases associated with it.
The document also asked specifically for the eventual merger of the tirzepatida.
This is the kind of initiative that shows how the topic is also gaining ground in political and social issues.
But the requirements of the municipal does not mean that there is a national policy to be passed.
Tirzepatida in the unified health system-SUS, may reduce inequality in access?
This is one of the arguments put forward by those who are advocates for expanding access to modern medicines for obesity.
Today, the price is limited to the treatment for a lot of people who might be able to have an indication from the body.
In a universal system, zoom options, has the potential to allow for that treatment is not to be restricted only to those who are unable to pay for the private market.
On the other hand, managers need to consider how to finance high-cost medical care to a population that is very large.
This is a balance between:
to access, efficiency, effectiveness, cost, and sustainability
it is in fact one of the major challenges of public health policy.
It's not just about delivering a pen
The other important thing to remember is that the Tirzepatida in the unified health system-SUSif it is built-in in the future, most likely it would need to be part of a broader strategy.
Obesity is a chronic multi-factorial.
Your treatment may include:
- power
- physical activity;
- psychological support;
- the control of co-morbid conditions;
- education public health;
- drugs
- surgery-in some cases as well.
Even prior to the Conitec involving drugs for obesity, highlighted the importance of integrating pharmacological therapies for the actions of multi-professional.
The treatment can be a long-term
This is a challenge for the economy.
Studies have shown that the removal of the modern medicines for obesity may be followed by the recovery of a significant portion of the weight is lost.
This brings up an important question for the systems in the public sector?
how long does the treatment need to be provided?
Thousands of people will need to use a drug during a period of several years, the cumulative cost can be very different from the one-of-a therapy in the short-term.
This has been one of the main concerns raised during the previous evaluation of the Conitec with other drugs for obesity.
The price may drop in the future.
It is possible to.
The market for the drug-related GLP-1 is rapidly changing.
The new molecules, manufacturers, competition, and the loss of patents on certain technologies that may change the prices of the course of the next few years.
A significant reduction of the price, I could change the analysis of the cost-effectiveness and the impact on the budget.
Because of this, a decision has been made today do not necessarily represent the scene over the next five years.
What needs to be done now?
In the case of the LG 590/2026 is the next step in the progress of the commissions of the Chamber.
In the situation of an official as of now is to wait for the appointment of a rapporteur to the Commission on Health care.
Later, the project still has to go through the other steps of the method.
So long as there is the approval and regulation, it is still only a proposal.
The traditional way of incorporation of the Tirzepatida in the unified health system-SUSit would also be necessary in the formal assessment for the Conitec, and the decision of the Ministry of Health.
How to keep track of the latest news?
The best sources are official channels.
The design of the law, can be traced directly to the page LG 590/2026 on the website of the house of Representatives.
The possible evaluations of the merger, it is worth to refer to the Conitec.
And for you information about the indications, registry, and security, and to the reference to regulations in brazil is the Fda.
Avoid relying solely on the movies, or the news headlines by saying that “Mounjaro has come to ITS” without checking to see if there's decree, or decision of the official.
Frequently asked questions
The Tirzepatida is now available for free in the unified health system-SUS?
No. As of August of 2026, there is no provision for national regular Tirzepatida in the unified health system-SUS for obesity or type 2 diabetes.
There is a project to make the Mounjaro free wi-fi.
Yes. The bill 590/2026 proposes to include Mounjaro, Zepbound and other medicinal products on the Program, the Pharmacy of the people.
The project has already been approved?
No. In August of 2026, and he was waiting for the designation of the rapporteur in the Committee on Health of the house of Representatives.
I can withdraw Mounjaro today, the people's Pharmacy?
No. Tirzepatida does not currently part of the squad in the official program.
There is the prediction of when it will be available?
There is no official date.
Approval by the Fda, means that the software may need to provide?
No. Regulatory approval and inclusion in the system is different.
The unified health system-SUS comes to obesity?
Yes. The system offers different strategies of treatment and follow-up, although medications such as tirzepatida yet they do not form part of the bid to the national regular.
The Tirzepatida in the SUS, to rely solely on the Congress?
Don't have to be. The traditional method for the incorporation of the technology involves the evaluation of the Conitec, and the decision of the Ministry of Health. The bill 590/2026 represents a legislative initiative in particular focused on the people's Pharmacy.
Conclusion
Discussion Tirzepatida in the unified health system-SUS advances have been made in 2026, with the presentation of a bill that proposes to include Mounjaro, Zepbound and other drugs-agonists of the GLP-1 into the Program, the Pharmacy of the people.
But it is important to differentiate between the proposal of the reality.
As of August of 2026, the bill 590/2026 are still waiting for the designation of the rapporteur in the Committee on Health, and had not become law.
Mounjaro too often today, the cast, the official from the people's Pharmacy.
Therefore, it is not correct to say that the Tirzepatida in the unified health system-SUS it is available free of charge on the in Brazil.
The issue, however, deserves a follow-up.
Obesity is a chronic disease that affects millions of people, drugs and modern, have brought new possibilities for the treatment of. At the same time, the prices are high, and the large number of patients to make it to the incorporation into the system of public decision-making complex.
In the coming months and years, the cost, the scientific evidence of financial sustainability, and the access policy is likely to remain at the center of this discussion.
For now, those looking for information on the Tirzepatida in the unified health system-SUS you must follow the decisions of the officers of the Chamber of Deputies, and the Conitec, and the Ministry of Health, and avoiding to interpret the project in progress as the policies that have already been approved.
References
- The house of Representatives by the Law no. 590/2026.
- The brazilian National agency of Sanitary Surveillance (Anvisa) — Mounjaro® (tirzepatida): re-appointment.
- The ministry of Health people's Pharmacy in Brazil.
- The ministry of Health's list of Drugs and supplies to the people's Pharmacy.
- The National committee for the Incorporation of Technologies into the unified health system-SUS (Conitec) recommendations, and evaluations of technology.
- Conitec — Semaglutida for the treatment of obesity, the decision-the end of the year 2025.
- Conitec — Protocol and Clinical Guidelines for Therapy of type 2 Diabetes Mellitus.
- Câmara Municipal de Mairinque — a request for a pen emagrecedoras by the public.
Content is up-to-date on the 25th of August, 2026.
Read On To Find Out
Nausea, with tirzepatida: is it normal?
Tirzepatida: what it is, how it works, and why everyone is talking about it
Tirzepatida in 2026: top 5 Major Trends-and what You Need to Know in order to Not Lose Muscle
Mounjaro or Ozempic? Make sure you understand the difference
11 Comments